TrialJournal for immunotherapy of cancer2023

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.

Xiaofeng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.